LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Variant classification summary
NM_001127208.3:c.5192del
TET2
· NP_001120680.1:p.(Gly1731AlafsTer14)
· NM_001127208.3
GRCh37: chr4:106196857 TG>T
·
GRCh38: chr4:105275700 TG>T
Gene:
TET2
Transcript:
NM_001127208.3
Final call
VUS
PVS1 strong
PM2 supporting
Variant details
Gene
TET2
Transcript
NM_001127208.3
Protein
NP_001120680.1:p.(Gly1731AlafsTer14)
gnomAD AF
ClinVar
OncoKB
Likely Oncogenic
Classification rationale
Interpretation summary
Generated evidence synthesis
1
PVS1 strong: the terminal-exon frameshift is predicted to truncate TET2 and escape canonical NMD.
2
PM2 supporting: the variant is absent from gnomAD v2.1 and v4.1.
Final determination:
Under the generic ACMG/AMP 2015 fallback, one strong pathogenic criterion plus one supporting criterion does not meet a Likely Pathogenic or Pathogenic combination rule, and no benign rule is satisfied, resulting in VUS.
Criteria assessment
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
| Criterion | Status | Rationale | Evidence used |
|---|---|---|---|
| PVS1 | Met | Strong: The frameshift in exon 11 of 11 is predicted to escape NMD, so PVS1 is downgraded from very strong under the NMD-escape rule. |
pvs1_gene_context
pvs1_variant_assessment
pvs1_generic_framework
|
| PS1 | N/A | Not applicable: PS1 requires a missense variant, and this is a frameshift variant. |
generic_acmg_combination_rules
|
| PS2 | Not assessed | Not assessed: confirmed maternity, paternity, proband disease status, and absence of family history are not documented. |
|
| PS3 | Not assessed | Not assessed: no validated assay directly tested c.5192del, and the available study assayed different TET2 mutants rather than this variant. |
PMID:21057493
|
| PS4 | Not assessed | Not assessed: no variant-specific affected-case/control counts, odds ratio, or 95% confidence interval were available to test the PS4 threshold OR > 5.0 with CI excluding 1.0. |
PMID:21057493
|
| PM1 | N/A | Not applicable: PM1 requires a missense variant, and this is a frameshift variant. |
generic_acmg_combination_rules
|
| PM2 | Met | Met at supporting strength: the variant is absent from gnomAD v2.1 and v4.1, satisfying the supplied PM2 frequency threshold of <=0.0001. |
gnomad_v2
gnomad_v4
|
| PM3 | Not assessed | Not assessed: no documented pathogenic allele in trans or parent/offspring testing establishes phase for this variant. |
|
| PM4 | N/A | Not applicable: PM4 requires a protein-length change, and this is a frameshift variant. |
pvs1_generic_framework
generic_acmg_combination_rules
|
| PM5 | N/A | Not applicable: PM5 requires a missense variant, and this is a frameshift variant. |
generic_acmg_combination_rules
|
| PM6 | Not assessed | Not assessed: no documented assumed de novo occurrence or parental testing is available for the proband. |
|
| PP1 | Not assessed | Not assessed: no affected relatives, familial testing results, cosegregation observations, or informative meioses are documented. |
|
| PP2 | N/A | Not applicable: PP2 requires a missense variant, and this is a frameshift variant. |
generic_acmg_combination_rules
|
| PP3 | N/A | Not applicable: c.5192del is a frameshift predicted to cause p.(Gly1731AlafsTer14), outside PP3's missense or splice-region/intronic scope. |
|
| PP4 | Not assessed | Not assessed: the patient's phenotype and family history were not provided, so phenotype specificity for a single-gene disease cannot be evaluated. |
|
| PP5 | Not met | Not met: ClinVar has no exact-variant record or expert-panel Pathogenic/Likely pathogenic classification to support PP5. |
clinvar
|
| BA1 | Not met | Not met: gnomAD v2.1 and v4.1 report the variant absent, with no grpmax FAF reaching the BA1 threshold of 0.05. |
gnomad_v2
gnomad_v4
|
| BS1 | Not met | Not met: gnomAD v2.1 and v4.1 report no observed alleles, so no grpmax FAF exceeds the generic BS1 threshold of 0.01. |
gnomad_v2
gnomad_v4
|
| BS2 | Not assessed | Not assessed: no healthy-adult carrier or homozygote observation is reported, and early-age full penetrance is not established for this disorder. |
gnomad_v2
gnomad_v4
|
| BS3 | Not assessed | Not assessed: no direct functional study shows that c.5192del has no damaging effect on TET2 function or splicing. |
PMID:21057493
|
| BS4 | Not assessed | Not assessed: no affected relatives with negative variant testing or pedigree evidence demonstrates lack of segregation. |
|
| BP1 | N/A | Not applicable: BP1 requires a missense variant, and this is a frameshift variant. |
generic_acmg_combination_rules
|
| BP2 | Not assessed | Not assessed: no phase-resolved observation shows a pathogenic variant in cis or, for a fully penetrant dominant disorder, in trans. |
|
| BP3 | N/A | Not applicable: BP3 requires an in-frame indel in a repeat region, and this is a frameshift variant. |
pvs1_generic_framework
generic_acmg_combination_rules
|
| BP4 | N/A | Not applicable: the frameshift predicts p.(Gly1731AlafsTer14), so SpliceAI max delta 0.011 cannot establish no gene-product impact under BP4. |
|
| BP5 | Not met | Not met: COSMIC reports one somatic occurrence, but no case with an established alternate molecular basis for the disease was documented. |
cosmic
|
| BP6 | Not met | Not met: ClinVar has no exact-variant record or expert-panel Benign/Likely benign classification to support BP6. |
clinvar
|
| BP7 | N/A | Not applicable: BP7 requires a synonymous variant, and this is a frameshift variant. |
generic_acmg_combination_rules
|
Disclaimer:
The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.